GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (FRA:ASZ1) » Definitions » Forward PE Ratio

Alimera Sciences (FRA:ASZ1) Forward PE Ratio : 108.78 (As of May. 11, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences Forward PE Ratio?

Alimera Sciences's Forward PE Ratio for today is 108.78.

Alimera Sciences's PE Ratio without NRI for today is 0.00.

Alimera Sciences's PE Ratio for today is 0.00.


Alimera Sciences Forward PE Ratio Historical Data

The historical data trend for Alimera Sciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Forward PE Ratio Chart

Alimera Sciences Annual Data
Trend 2020-12 2021-08 2023-12 2024-05
Forward PE Ratio
29.76 121.95 18.08 116.28

Alimera Sciences Quarterly Data
2020-12 2021-06 2023-09 2023-12 2024-03
Forward PE Ratio 29.76 149.25 6.74 18.08 43.48

Competitive Comparison of Alimera Sciences's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alimera Sciences's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's Forward PE Ratio falls into.



Alimera Sciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Alimera Sciences  (FRA:ASZ1) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Alimera Sciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alimera Sciences (FRA:ASZ1) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (FRA:ASZ1) Headlines

No Headlines